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Background: Male breast cancer is a rare malignancy. Despite the lack of prospectively generated data from trials
in either the adjuvant or metastatic setting, patients are commonly treated with hormone therapies. Much controversy
exists over the use of gonadotropin-releasing hormone analogues in metastatic male breast cancer patients. We conducted
this study to provide more concrete ground on the use of gonadotropin-releasing hormone analogues in this setting.
Methods: We herein present results from a pooled analysis including 60 metastatic male breast cancer patients treated
with either an aromatase inhibitor or cyproterone acetate as a monotherapy (23 patients) or combined with a
gonadotropin-releasing hormone analogue (37 patients).
Results: Overall response rate was 43.5 % in patients treated with monotherapy and 51.3 % with combination therapy
(p = 0.6). Survival outcomes favored combination therapy in terms of median progression-free survival (11.6 months
versus 6 months; p = 0.05), 1-year progression-free survival rate (43.2 % versus 21.7 %; p = 0.05), median overall survival
(29.7 months versus 22 months; p = 0.05), and 2-year survival rate (64.9 % versus 43.5 %; p = 0.05).
Conclusions: In metastatic male breast cancer patients, the combined use of gonadotropin-releasing hormone analogues
and aromatase inhibitors or antiandrogens seems to be associated with greater efficacy, particularly in terms of survival
outcomes, compared with monotherapy. Collectively, these results encourage considering these agents in the metastatic
setting.
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Male breast cancer (MBC) is an uncommon malignancy
accounting for less than 1 % of all breast cancer (BC)
cases [1], albeit its incidence is rising [2]. The hormone-
driven nature of the disease was postulated in the 1940s
[2] and corroborated over the past decades by studies
reporting on hormone receptor expression [3, 4]. Results
from the National Cancer Institute’s Surveillance, Epi-
demiology, and End Results (SEER) database revealed* Correspondence: maugeri@ifo.it
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unless otherwise stated.that 92 % of MBC cases were estrogen receptor-positive
[4]. Thus, antiestrogen therapy currently represents the
mainstay of treatment for these patients, even though
the use of tamoxifen [5], aromatase inhibitors (AIs)
[6–8], and fulvestrant [9, 10] was investigated only retro-
spectively in small-sized cohorts. A therapeutic role for
the androgen receptor (AR) was also envisioned [11–13]
and corroborated by immunohistochemical analysis and
gene-expression-profiling studies [3, 14]. Analysis of a
large MBC cohort documented AR immunoreactivity in
64 % of cases [3], and over-expression of AR-related
pathway components was reported [14].
Despite the wealth of hormonal treatments that have
entered the therapeutic arena, owing to the rarity of thisl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Association between clinical-pathological features and
treatment received (N = 60)
Characteristic With GnRH N (%) Without GnRH N (%) p value*
Age
Median 64 63 0.79
Range 24–82 29–76
ECOG PS
Median 1 1 0.88
Range 0–2 0–2
Hormone receptor
status
Positive 32 (86.5) 19 (82.6) 0.99
Negative 2 (5.5) 2 (8.7)
Unknown 3 (8) 2 (8.7)
Adjuvant systemic
therapy
Yes 19 (51) 10 (43.5) 0.60
No 18 (49) 13 (56.5)
Prior therapy for
metastatic disease
Yes 9 (24) 7 (30.5) 0.99
No 28 (76) 16 (69.5)
Subsequent lines of
CT
Median 1 1 0.72
Range 1–2 1–2
Subsequent lines of
HT
Median 1 1 0.85
Range 1–3 1–3
Dominant disease site
Viscera 24 (64.9) 14 (60.8)
Bone 9 (24.3) 8 (34.8) 0.98
Soft-tissue 4 (10.8) 1 (4.4)
Number of disease
sites
1 11 (29.7) 10 (43.4)
2 21 (56.7) 9 (39.1) 0.99
≥ 3 5 (13.6) 4 (17.5)
ECOG PS: Eastern Cooperative Oncology Group Performance Status; CT:
chemotherapy; HT: hormone therapy
*Fisher exact test
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ber of unsolved questions afflict daily clinical practice. A
heated argument surrounds the question of whether
gonadotropin-releasing hormone analogues (GnRH ana-
logues) are worth being administered in combination
with other hormonal treatments acting on peripheral
targets [7, 8, 13]. This controversy was fuelled by the ad-
vent of AIs [15]. In males, AIs lead to increased levels of
follicle-stimulating hormone (FSH), luteinising hormone
(LH), and testosterone (T) [16–20]. This phenomenon
was observed in hypogonadal men and MBC patients
[16–20]. For MBC patients, implications of increased T
levels are twofold: i) the counteraction of the block im-
posed by AIs through an excess of substrate and ii) a dir-
ect stimulation of cancer cells equipped with the AR [21].
Briefly, the inhibition of the hypothalamic-pituitary feed-
back loop, with the correlated reduction of the substrate
for aromatization, was the rationale for combining AIs
with GnRH analogues. A second, though underestimated,
association strategy relates to the use of GnRH analogues
with antiandrogens [12, 13]. Our group reported on the
antitumor activity of antiandrogens [11, 12], a finding we
recently strengthened in a larger series where hints on the
existence of an association between AR expression and
clinical outcomes were also provided [13]. In this case, the
use of antiandrogens with a GnRH analogue stemmed
from the need to neutralize testicular and adrenal andro-
gens, theorizing analogies in terms of androgen depend-
ency between MBC and prostate cancer [13]. Indeed, our
group already reported on the suppression of gonadotro-
pins together with T suppression to castration levels in
MBC patients who received cyproterone acetate (CPA)
with buserelin [12]. These effects were also observed, al-
though to a lower extent, with CPA monotherapy [11].
Therefore, there is a common theme underlying the use of
GnRH analogue with antiandrogens and AIs, namely, achiev-
ing the deepest possible T suppression to directly or indir-
ectly deprive cancer cells of a source of oncogenic stimuli, in
the latter case by preventing the conversion of androstene-
dione to 17b-estradiol operated by the aromatase enzyme.
By evaluating metastatic MBC (mMBC) treated with an
AI or CPA [8, 13], administered alone or combined with a
GnRH analogue, we previously noted some differences fa-
voring the association. Nevertheless, the relatively re-
stricted number of patients analyzed hindered statistically
significant comparisons. Prompted by this observation, we
herein present results from a pooled analysis of these stud-
ies, with the inclusion of five additional patients, in order
to gain more insights into the efficacy of GnRH analogue-
containing hormonal therapy in mMBC patients.
Results
Sixty men mostly treated in the first-line metastatic setting
were included in the present analysis.Patients’ characteristics are illustrated in Table 1. As
shown in Table 1, the groups compared did not differ by
any of the variables considered. Overall, 37 patients re-
ceived GnRH analogue-containing therapy (22 patients
with CPA and 15 patients with an AI), and 23 patients
were treated with GnRH analogue-free therapy (14 patients
with CPA and 9 patients with an AI).
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20 (33.3 %), 21 (35 %), and 8 (13.4 %) patients, respect-
ively. Stage I–II at diagnosis was 48 % in the monother-
apy group and 52 % in the combination group. Overall,
29 patients received adjuvant systemic therapy, 10 in the
monotherapy group (43.5 %) and 19 in the combination
group (51 %). In the adjuvant setting, ten patients were
treated with chemotherapy, ten patients with hormone
therapy, and nine patients with both chemotherapy and
hormone therapy. Adjuvant hormone therapy consisted
of tamoxifen in all but one patient who received goserelin.
Adjuvant chemotherapy consisted of cyclophosphamide,
methotrexate, and 5-fluorouracil (CMF) in 11 patients;
5-fluorouracil, doxorubicin, and cyclophosphamide or
5-fluorouracil, epirubicin, and cyclophosphamide (FAC or
FEC, respectively) in 5 patients; or epirubicin, cyclophos-
phamide, docetaxel (EC-D) in 3 patients. Sixteen patients
received previous chemotherapy and/or hormone therapy
for metastatic disease: 7 out of 23 (30.5 %) in the mono-
therapy group and 9 out of 37 (24 %) in the combination
group. The characteristics of these treatments, along with
clinical outcomes, were reported in detail elsewhere
[8, 13]. Five patients treated in the first-line setting with
an AI in monotherapy were retreated with an AI in associ-
ation with a GnRH analogue after disease progression.
These patients were included in the monotherapy group
in the present analysis.
Overall response rate was 51.3 % (19/37 patients) in pa-
tients treated with combination versus 43.5 % with mono-
therapy (10/23 patients). The difference observed was not
statistically relevant (p = 0.6). Median progression-free sur-
vival (mPFS) was 11.6 months (95 % CI = 10.2–13) in the
group having received the GnRH analogue-containing
combination and 6 months (95 % CI = 4–8) for patientsFig. 1 Kaplan–Meier curves of a PFS and b OS comparing monotherapy (Ctreated with monotherapy (p = 0.05) (Fig. 1). One-year
progression-free survival (PFS) rate also favored combin-
ation (43.2 % versus 21.7 %; p = 0.05). Median overall sur-
vival (mOS) was 29.7 months with combination (95 % CI =
20.4–39) and 22 months (95 % CI = 15.9–28.1) with mono-
therapy (p = 0.05) (Fig. 1). Two-year survival rate was
64.9 % in the combination group versus 43.5 % in the
monotherapy group (p = 0.05).Discussion
Evidence on the therapeutic role of GnRH analogue as a
partner for other hormonal agents in mMBC are scat-
tered, gathered from case reports or small retrospective
series, and overall inconsistent [7, 8, 13, 15]. More gen-
erally, therapeutic decision-making for mMBC is not
built upon level I evidence, and without appearing nihil-
istic, we do not foresee brighter scenarios in the near fu-
ture. Not surprisingly, then, there is no agreement on
whether GnRH analogues should be considered an inte-
gral part of the therapeutic armamentarium, or rather,
their use should be evaluated on a case-by-case basis
[21, 22]. Anticipating that our results, which are retro-
spective in nature, are not intended to provide a defini-
tive answer on that issue, to the best of our knowledge,
this is the largest series presented so far describing the
activity of GnRH analogue-containing therapy.
Before discussing our results, two introductive consider-
ations need to be presented. As previously discussed else-
where, we were unable to retrieve safety data for all patients
included [8, 13]. However, when available, toxicities data
were consistent with the expected frequency and severity.
In addition, out-of-date imaging techniques and criteria for
response evaluation were used in a fraction of patients.PA or AI) versus combination therapy containing a GnRH analogue
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lyzing the therapeutic potential of GnRH analogues, we
would like to draw the reader’s attention to the line of
reasoning that stimulated this study. We grouped pa-
tients treated with an AI or CPA as a monotherapy and
compared them with patients that also received a GnRH
analogue. As mentioned above, the logic behind this was
the placement of T at the centerpiece of the endocrine
network feeding MBC. Coherently, control of T levels is
unsatisfactory in the case of exclusive use of CPA [23],
or they even increase when AIs are administered in
monotherapy [16–20]. Adding a GnRH analogue to per-
ipherally acting antiestrogens and antiandrogens shares
the same logic and produces the same output, that is,
suppressing androgens [21, 23].
With the limitations of any retrospective and indirect
comparison, we herein report a trend towards statistical
significance favoring the use of GnRH analogue for all
the survival endpoints considered. In order to put our
results into context, it is worth considering that mPFS
and mOS reported with combination therapy were fairly
comparable with those previously observed with AIs,
which were in the range of 4.4–13 and 33–39 months,
respectively, independently on whether AIs were com-
bined with a GnRH analogue or not [6–8]. These results
are rooted, in our opinion, in the fact than more than half
of the patients in this study received antiandrogen-based
therapy mostly between the 1970s and 1980s [11–13].
With this therapeutic approach, mPFS was rather similar
(8.9 months) to that observed with AIs, whereas mOS was
shorter (24.3 months). Intuitively, this divergent pattern
suggests that patients treated with antiandrogen-containing
therapy were more likely to have received outdated post-
progression treatments and possibly suboptimal supportive
care, as already detailed [13]. In other words, the inclusion
in the present analysis of patients treated at the dawning
of antihormone therapy probably diluted the advantages
potentially deriving from the use of GnRH analogues.
Secondly and non-negligibly, five patients (~20 %), of
whom four were previously presented in [8], included in
the monotherapy group who received an AI as a first-line
therapy were rechallenged with an AI plus a GnRH
analogue following disease progression. Notably, four out
five of them confirmed or improved the best overall re-
sponse observed in the previous therapeutic line with AI
monotherapy. We cannot therefore exclude a role for
such a sequential approach in diluting treatment efficacy
and ultimately flattening survival curves.
Conclusions
We are aware that no firm conclusions can be drawn from
this study, as the evidence provided does not meet criteria
to settle the debate on the usefulness of GnRH analogues.
On the other hand, however, clues emerging from thisanalysis encourage clinicians to consider GnRH analogues
in the therapeutic continuum, irrespectively of the thera-
peutic “backbone” used. Finally, a provocative question
arose that is whether, in pursuing the goal of sequential
hormonal therapy for delaying chemotherapy, GnRH ana-
logues shall deserve substantially increased consideration
as singularly deliverable agents.Methods
In the present study, we evaluated a population of 60
mMBC patients who had received an AI or CPA mostly in
the first-line setting, administered as a monotherapy or
combined with a GnRH analogue. The majority of patients
were clinically managed at the “Regina Elena” National
Cancer Institute, Rome. Individual patient data were
reviewed in order to retrieve information on demographic
factors, molecular pathology, therapies, and treatment out-
comes. Patients received the following treatments: letrozole
2.5 mg orally daily as a monotherapy or with leuprolide
acetate or triptorelin acetate given intramuscularly at
3.75 mg every 28 days, CPA 100 mg twice a day as a mono-
therapy or combined with buserelin administered subcuta-
neously at 1500 μg daily in three doses during the first
week and then reduced to 600 μg a day or Goserelin ad-
ministered at 3.6 mg subcutaneously every 28 days, exe-
mestane 25 mg once daily or anastrozole 1 mg once a
day. Tumor response was evaluated according to the cri-
teria outlined by the International Union Against Cancer
[24], the World Health Organization [25], or the Re-
sponse Evaluation Criteria In Solid Tumors (RECIST 1.1)
coherently to the period when patients were treated.
Progression-free survival (PFS) and overall survival (OS)
were calculated from the date of therapy initiation to the
date of disease progression or death from any cause, re-
spectively. PFS and OS were analyzed according to the
Kaplan–Meier method. Comparisons between groups
were carried out with the Tarone–Ware test. Statistical
analyses were performed using SPSS statistical software
version 20 (SPSS inc., Chicago IL, USA). This study was
approved by the Ethics Committee of “Regina Elena”
National Cancer Institute of Rome and was carried out
according to the Helsinki Declaration.Abbreviations
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